Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

682930.pdf (12.36 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2018-10-10

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126377

A Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1021/jacs.8b08249

Resum

The efficacy and tolerability of systemically administered anticancer agents are limited by their off-target effects. Precise spatiotemporal control over their cytotoxic activity would allow improving chemotherapy treatments, and light-regulated drugs are well suited to this purpose. We have developed phototrexate, the first photoswitchable inhibitor of the human dihydrofolate reductase (DHFR), as a photochromic analogue of methotrexate, a widely prescribed chemotherapeutic drug to treat cancer and psoriasis. Quantification of the light-regulated DHFR enzymatic activity, cell proliferation, and in vivo effects in zebrafish show that phototrexate behaves as a potent antifolate in its photoactivated cis configuration and that it is nearly inactive in its dark-relaxed trans form. Thus, phototrexate constitutes a proof-of-concept to design light-regulated cytotoxic small molecules and a step forward to develop targeted anticancer photochemotherapies with localized efficacy and reduced adverse effects

Matèries

Artritis reumatoide, Psoriasi, Càncer, Fototeràpia, Fotoquimioteràpia, Nanomedicina

Matèries (anglès)

Rheumatoid arthritis, Psoriasis, Cancer, Phototherapy, Photochemotherapy, Nanomedicine

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC))

Citació

MATERA, Carlo, et al. A Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy. Journal of the American Chemical Society. 2018. Vol. 140, num. 46, pags. 15764-15773. ISSN 0002-7863. [consulted: 11 of August of 2026]. Available at: https://hdl.handle.net/2445/126377

Exportar metadades

JSON - METS

Compartir registre